Navigation Links
ISTO Technologies Awarded Key Patent for NuQu™ Injectable Therapy for Degenerative Disc Disease
Date:2/7/2011

ST. LOUIS, Feb. 7, 2011 /PRNewswire/ -- ISTO Technologies, Inc. announced today that the United States Patent and Trademark Office (USPTO) has granted the company a key patent covering the primary technology for ISTO's NuQu™ product.  The new patent, issued on February 1, 2011 as Patent # US-7,879,604, covers the method of cultivating juvenile cartilage cells and injecting those cells into a disc nucleus for the treatment of degenerative disc disease.  

NuQu is an injectable cell-based therapy derived from ISTO's cartilage regeneration platform technology.  It is intended for use as an early intervention treatment for patients suffering from lower back pain.  In preclinical studies, the juvenile chondrocytes used in the NuQu program have shown to be up to 100 times more efficient in producing cartilage matrix than adult cartilage cells.

"The receipt of this patent is an important milestone for the company and is the result of the hard work of many dedicated people over several years.  We believe that our proprietary juvenile chondrocyte-based technology represents a significant potential new treatment option for patients with chronic lower back pain.  Accordingly, an important part of our strategy is to develop a strong intellectual property base to support our product development efforts. We view this recognition by the USPTO of our novel and unique technology as a significant step forward for the NuQu program and for the Company," said Mitchell Seyedin, Ph.D. President & CEO of ISTO.

The company announced the completion of patient enrollment in the Phase I clinical study for NuQu in October 2010.  The study consists of fifteen (15) patients enrolled at two clinical sites. The company anticipates completing data collection of six-month interim results from the trial in early 2011.  All patients enrolled in the trial suffered from persistent discogenic back pain and disability despite undergoing previous traditional conservative therapies.

In addition to NuQu, the company's other product derived from its cartilage regeneration platform is DeNovo® ET, a scaffold-free engineered cartilage tissue, intended for the repair of damaged articular cartilage in the knee.  DeNovo® ET is developed in partnership with Zimmer, the world's largest provider of reconstructive solutions, and is currently in clinical trials.

In addition to ISTO's cell-based cartilage programs, the company is currently producing and marketing InQu®, a bone graft extender and substitute.  InQu combines integrated hyaluronic acid and a resorbable polymer for better handling and biology. The primary target market for InQu is spinal fusion applications.

About ISTO ISTO is a privately-held orthobiologics company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone.  For additional information on ISTO, please visit our website at www.istotech.com. ISTO Technologies, Inc.

Scott Gill

Chief Financial Officer

(314) 995-6049The Ruth Group

Zack Kubow (investors)

(646) 536-7020

zkubow@theruthgroup.comKimberly Muscara (media)

(646) 536-7011

kmuscara@theruthgroup.com
'/>"/>

SOURCE ISTO Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Palatin Technologies Listing Compliance Plan Accepted by NYSE Amex
2. China Medical Technologies to Announce Results for the Third Fiscal Quarter Ended December 31, 2010 on February 18, 2011
3. Long-Term European Data Released for SUPERA® Stent from IDEV Technologies
4. Wound Management Technologies Announces Secure eHealth Technology to be Included During HIMSS 2011 Interoperability Showcase
5. Reportlinker Adds European Markets for Assisted Living Technologies
6. PharmAthene Provides Update on Litigation With SIGA Technologies
7. Advanced Assay Technologies and Development Methods
8. Intrasphere Technologies to Help Develop and Deliver Global Partner Training for the Oracle(R) Argus Safety Suite Through Oracle PartnerNetwork
9. RF Technologies® Announces Distributor Agreement With Universal Hospital Services
10. Nopras Technologies, Inc. Achieves ISO 9001:2008 Certification
11. Hotspur Technologies Continues to Bring Innovations to Peripheral Vascular Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
Breaking Medicine News(10 mins):